Delcath Systems (DCTH) AI Stock Analysis

• Market Cap: $306.52M
• Dividend Yield: N/A
• Average Volume (3M): 1.07M
• Price to Earnings (P/E): 1004.7
• Beta (1Y): 1.63
• Revenue Growth: 251.54%
• EPS Growth: N/A
• Country: US
• Employees: 96
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.02
• Shares Outstanding: 35,313,717
• 10 Day Avg. Volume: 1,263,012
• 30 Day Avg. Volume: 1,066,127
• PEG Ratio: 0.19
• Price to Book (P/B): 4.99
• Price to Sales (P/S): 9.23
• P/FCF Ratio: -17.84
• Enterprise Value/Market Cap: 1.12
• Enterprise Value/Revenue: 5.80
• Enterprise Value/Gross Profit: 4.99
• Enterprise Value/Ebitda: 24.33
• 1Y Price Target: $25.50
• Price Target Upside: 195.14% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: $9.50 ▲(9.95% Upside)

Delcath Systems' overall stock score is driven by strong financial performance and positive earnings call highlights, including revenue growth and clinical trial advancements. However, the high valuation and bearish technical indicators weigh negatively on the score.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful market penetration and product adoption, supporting long-term business expansion.

Cash Position

A robust cash position with no debt enhances financial stability, providing flexibility for strategic investments and growth.

Clinical Trials Expansion

Expanding clinical trials into new indications can drive future growth and diversify revenue streams, strengthening market position.

Negative Factors

Delayed Site Activations

Delays in site activations could slow revenue growth and market expansion, impacting the company's ability to meet strategic goals.

Increased R&D Expenses

Rising R&D expenses may pressure margins and profitability, requiring careful management to ensure sustainable financial performance.

Revenue Guidance Adjustment

Lowered revenue guidance reflects operational challenges, potentially affecting investor confidence and future financial projections.

Delcath Systems Business Overview & Revenue Model

Company Description

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

How the Company Makes Money

Delcath Systems generates revenue primarily through the sale of its Chemosaturation Technology System and associated consumables used in its procedures. The company may also earn revenue through collaborations, licensing agreements, and grants related to the development and commercialization of its therapies. Key revenue streams include reimbursement from healthcare providers and insurance companies for the use of its CTS in clinical settings. Additionally, strategic partnerships with research institutions or pharmaceutical companies can provide funding and support for clinical trials, which may further enhance Delcath's market presence and revenue potential.

Delcath Systems Financial Statement Overview

Summary

Delcath Systems shows strong revenue growth and improved profitability, supported by a stable balance sheet with low leverage. However, historical volatility in profitability and cash flow generation poses potential risks.

Income Statement

Delcath Systems has shown a strong revenue growth rate of 31.39% in the TTM, indicating a positive trajectory in sales. The company has improved its profitability with a net profit margin of 5.02% and a gross profit margin of 135.70%, reflecting efficient cost management. However, historical data shows volatility with previous negative margins, suggesting potential risks in maintaining consistent profitability.

Balance Sheet

The balance sheet is stable with a low debt-to-equity ratio of 0.009, indicating minimal leverage and financial risk. The return on equity is modest at 3.40%, showing moderate efficiency in generating returns from equity. The equity ratio stands at 89.82%, suggesting a strong equity base relative to total assets. However, historical fluctuations in equity and returns highlight potential risks in financial stability.

Cash Flow

The cash flow statement shows a decline in free cash flow growth at -151.02%, indicating challenges in generating cash. The operating cash flow to net income ratio of 0.46 suggests moderate cash generation efficiency. Despite a positive free cash flow to net income ratio of 0.80, historical negative cash flows highlight potential liquidity risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	59.04M	37.20M	2.06M	2.72M	3.56M	1.65M
Gross Profit	68.69M	31.02M	1.43M	2.03M	2.88M	1.01M
EBITDA	14.08M	-12.18M	-46.11M	-33.69M	-24.00M	-23.79M
Net Income	1.20M	-26.39M	-47.68M	-39.16M	-26.76M	-24.48M
Balance Sheet
Total Assets	124.30M	76.59M	38.61M	17.86M	33.12M	34.63M
Cash, Cash Equivalents and Short-Term Investments	88.91M	53.23M	32.45M	7.67M	22.80M	28.57M
Total Debt	965.00K	1.04M	10.19M	15.87M	16.25M	2.94M
Total Liabilities	9.45M	7.84M	22.84M	23.72M	21.17M	12.56M
Stockholders Equity	114.85M	68.75M	15.78M	-5.86M	11.95M	22.08M
Cash Flow
Free Cash Flow	12.04M	-19.24M	-31.31M	-25.16M	-22.75M	-23.65M
Operating Cash Flow	13.26M	-18.68M	-31.25M	-24.95M	-22.60M	-22.87M
Investing Cash Flow	-41.26M	-981.00K	-19.71M	-209.00K	-143.00K	-782.00K
Financing Cash Flow	61.38M	39.41M	51.78M	10.14M	20.82M	42.35M

Delcath Systems Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.64
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DCTH, the sentiment is Negative. The current price of 8.64 is below the 20-day moving average (MA) of 10.38, below the 50-day MA of 10.79, and below the 200-day MA of 12.72, indicating a bearish trend. The MACD of -0.57 indicates Positive momentum. The RSI at 30.51 is Neutral, neither overbought nor oversold. The STOCH value of 12.24 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DCTH.

Delcath Systems Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLPT	60 Neutral	$482.70M	-22.81	-85.68%	―	19.68%	-13.17%
DCTH	58 Neutral	$306.52M	1,004.65	1.94%	―	251.54%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TMCI	50 Neutral	$411.89M	―	-46.89%	―	7.67%	23.79%
SENS	45 Neutral	$272.51M	―	-129.29%	―	31.94%	36.59%
SRDX	43 Neutral	$393.18M	―	-15.36%	―	-0.02%	-1196.44%
NNOX	40 Underperform	$207.86M	―	-32.87%	―	17.36%	9.38%

Delcath Systems Corporate Events

Delcath Systems Reports Strong Q3 2025 Growth

Delcath Systems, Inc. is an interventional oncology company specializing in the treatment of primary and metastatic liver cancers through its proprietary products, HEPZATO KIT and CHEMOSAT, which deliver high-dose chemotherapy to the liver while minimizing systemic exposure.

Delcath Systems’ Promising Study on Liver-Directed Chemotherapy for Colorectal Cancer

Delcath Systems, Inc. is conducting a clinical study titled ‘An Open-label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction Treatment With Melphalan/HDS Followed by Consolidation Treatment With Trifluridine-Tipiracil Plus Bevacizumab Versus Trifluridine-Tipiracil Plus Bevacizumab Alone in Patients With Refractory Metastatic Colorectal Cancer With Liver Dominant Disease.’ The study aims to assess the safety and effectiveness of a liver-directed high-dose chemotherapy treatment followed by standard cancer therapy compared to standard therapy alone in patients with metastatic colorectal cancer that has spread to the liver.

Delcath Systems’ New Study on Liver-Directed Chemotherapy for Metastatic Breast Cancer

Delcath Systems, Inc. has announced a new clinical study titled An Open-label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction Treatment With Melphalan/HDS Followed by Consolidation Treatment With Eribulin or Vinorelbine or Capecitabine Versus Eribulin or Vinorelbine or Capecitabine Alone in Patients With Metastatic Breast Cancer With Liver Dominant Disease. The study aims to assess the safety and efficacy of a liver-directed therapy using high-dose chemotherapy for patients with metastatic breast cancer that has spread to the liver. This research is significant as it explores potential advancements in treatment options for this challenging condition.

Delcath Systems Reports Positive CHOPIN Trial Results

On October 18, 2025, Delcath Systems announced the results of the CHOPIN Trial, which showed that the combination of their CHEMOSAT Hepatic Delivery System with immune checkpoint inhibitors significantly improved progression-free survival in patients with metastatic uveal melanoma compared to PHP alone. Additionally, Delcath reported preliminary third-quarter financial results, revealing a total revenue of approximately $20.5 million, a net income of $0.8 million, and positive cash flow, indicating a strong financial position with no debt as of September 30, 2025.

The most recent analyst rating on (DCTH) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Delcath Systems stock, see the DCTH Stock Forecast page.

Delcath Systems Updates Bylaws for Governance Efficiency

On August 12, 2025, Delcath Systems, Inc. amended and restated its Bylaws to clarify procedural requirements for stockholder nominations and proposals, update officer election provisions, and describe indemnification rights. These changes aim to modernize and streamline the company’s governance framework, potentially impacting its operational efficiency and stakeholder engagement.

The most recent analyst rating on (DCTH) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Delcath Systems stock, see the DCTH Stock Forecast page.

Delcath Systems Reports Strong Q2 2025 Results

Delcath Systems, Inc. is an interventional oncology company specializing in the treatment of primary and metastatic liver cancers, utilizing its proprietary HEPZATO KIT and CHEMOSAT systems to deliver high-dose chemotherapy directly to the liver while minimizing systemic exposure.

Delcath Systems Reports Strong Q2 Growth Amid Challenges

Delcath Systems, Inc. recently held its second-quarter earnings call, revealing a balanced outlook for the company. While there was notable revenue growth and positive cash flow, challenges such as slower site activations and increased expenses were acknowledged. Adjustments in financial guidance due to the 340B program also posed potential hurdles. However, the company’s proactive initiatives in research and development and pipeline expansion position it well for future growth.